Dr. Bernd Goergen

Dr. Bernd Goergen

Dr Bernd Goergen, Partner, has been a part of High-Tech Gründerfonds’ Life Science Team since early 2008. He holds a PhD in biology and is a certified biotech analyst with the German Association for Financial Analysis and Asset Management (DVFA). He brings with him five years of research experience in the field of virology and immunology and seven years in international diagnostics marketing for German and international companies. Between 2000 and 2007, Dr Goergen also acquired extensive knowledge in M&A and capital market deals while working in the investment banking division of a major German bank.


+49 –(0)228 – 82300 – 136


Posts & mentions

18. December 2020

How passion and expertise led to a billion-euro exit

As a High-Tech Gründerfonds (HTGF) partner, Dr. Bernd Goergen has just signed the most successful exit in HTGF history. US pharmaceutical company Gilead Sciences is set to acquire German biotech start-up MYR for roughly EUR 1.15 billion. In this interview, he speaks about the fight against Hepatitis D, drug development and his own personal successes. Bernd, congratulations are in order! In 2011, HTGF took up a stake in MYR. And now you’re about to close a billion-eur
10. December 2020

Most Successful Exit in the History of High-Tech Gründerfonds - Gilead Sciences to Acquire MYR GmbH

One of the largest trade sales of a VC-financed German biotech start-up in the last 20 yearsMYR developed HepcludexTM (Bulevirtide), a first-in-class entry inhibitor for the treatment of chronic hepatitis delta virus (HDV). Hepcludex was conditionally approved in Europe by the EMA in July 2020 and submission for accelerated approval in the United States is anticipated by second half of 2021The acquisition builds on Gilead’s strength as a global leader in virology and liver diseases with ad
20. October 2020

Successful exit for High-Tech Gründerfonds and Bayern Kapital –
Proteintech acquires ChromoTek

Proteintech, which is based in Chicago, Illinois, USA, is the benchmark in antibodiesMartinsried-based startup ChromoTek is a market leader in nanobodiesThe acquisition enables Proteintech to expand its next-generation antibody toolsBayern Kapital and HTGF arranged the seed financing in 2010The transaction marks HTGF’s 10th successful exit during the coronavirus crisis High-Tech Gründerfonds and Bayern Kapital have sold their shares in ChromoTek after having spent 10 years at the start
15. September 2020

Successful Exit for High-Tech Gründerfonds – Intersect ENT acquires Fiagon

Buyer is the Intersect ENT, a medical technology company based in the USThe startup Fiagon AG Medical Technologies expands Intersects portfolio of ENT product offeringsFor the HTGF it is the 8th successful exit during the Corona crisis The High-Tech Gründerfonds sold its shares in Fiagon. The seed investor has accompanied the company for 11 years. The publicly traded company Intersect ENT (NASDAQ: XENT), Menlo Park, California, USA, is dedicated to transforming  the treatment of ear
6. April 2020

Why we need to see more investment diversity in the life sciences sector to overcome crises such as the current one

Dr. Bernd Goergen has been working at High-Tech Gründerfonds for the last 12 years. The HTGF Partner is an expert in the field of life sciences. His investment portfolio includes PEPperPRINT, a Heidelberg-based start-up which is making a valuable contribution to the fight against the coronavirus. In this interview, he sheds light on start-ups in the life sciences sector, pharmaceutical innovations and the importance of long-term investment strategies. Bernd, how is your portfolio co